BIOMAT Database Logo BIOMAT Database Logo

Rifaximin in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome. 2017

Cong Dai, and Min Jiang, and Ming-Jun Sun
Department of Gastroenterology, First Affiliated Hospital, China Medical University, Shenyang City, Liaoning Province, China.

UI MeSH Term Description Entries
D003967 Diarrhea An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight. Diarrheas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000078262 Rifaximin A synthetic rifamycin derivative and anti-bacterial agent that is used for the treatment of GASTROENTERITIS caused by ESCHERICHIA COLI INFECTIONS. It may also be used in the treatment of HEPATIC ENCEPHALOPATHY. 4-Deoxy-4'-methylpyrido(1',2'-1,2)imidazo(5,4C)rifamycin,L 105,L-105,Redactiv,Xifaxan,L105
D012294 Rifamycins A group of ANTI-BACTERIAL AGENTS characterized by a chromophoric naphthohydroquinone group spanned by an aliphatic bridge not previously found in other known ANTI-BACTERIAL AGENTS. They have been isolated from fermentation broths of Streptomyces mediterranei. Rifamycin,Rifomycin,Rifomycins
D043183 Irritable Bowel Syndrome A disorder with chronic or recurrent colonic symptoms without a clearcut etiology. This condition is characterized by chronic or recurrent ABDOMINAL PAIN, bloating, MUCUS in FECES, and an erratic disturbance of DEFECATION. Colitis, Mucous,Colon, Irritable,Colitides, Mucous,Irritable Bowel Syndromes,Irritable Colon,Mucous Colitides,Mucous Colitis,Syndrome, Irritable Bowel,Syndromes, Irritable Bowel

Related Publications

Cong Dai, and Min Jiang, and Ming-Jun Sun
Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome.
January 2016, Expert review of gastroenterology & hepatology,
Cong Dai, and Min Jiang, and Ming-Jun Sun
Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome.
December 2016, Gastroenterology,
Cong Dai, and Min Jiang, and Ming-Jun Sun
Pharmacokinetic drug evaluation of rifaximin for treatment of diarrhea-predominant irritable bowel syndrome.
July 2018, Expert opinion on drug metabolism & toxicology,
Cong Dai, and Min Jiang, and Ming-Jun Sun
Fecal bacteria can predict the efficacy of rifaximin in patients with diarrhea-predominant irritable bowel syndrome.
September 2020, Pharmacological research,
Cong Dai, and Min Jiang, and Ming-Jun Sun
[Treatment of Irritable Bowel Syndrome with Predominant Diarrhea].
April 2025, The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi,
Cong Dai, and Min Jiang, and Ming-Jun Sun
Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome.
March 2015, Expert opinion on pharmacotherapy,
Cong Dai, and Min Jiang, and Ming-Jun Sun
[Diarrhea predominant irritable bowel syndrome].
June 2008, La Revue du praticien,
Cong Dai, and Min Jiang, and Ming-Jun Sun
Treatment of diarrhea-predominant irritable bowel syndrome with paroxetine.
January 2005, Primary care companion to the Journal of clinical psychiatry,
Cong Dai, and Min Jiang, and Ming-Jun Sun
Rifaximin (Xifaxan) for irritable bowel syndrome with diarrhea.
August 2015, The Medical letter on drugs and therapeutics,
Cong Dai, and Min Jiang, and Ming-Jun Sun
Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome.
January 2017, Drug design, development and therapy,
Copied contents to your clipboard!